Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcome (ARTFORCE) EU 1.036 k€ Maastro Clinic
167k€ Maastro Innovations 2011-2015
Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy (QuIC-ConCePT)
EU, IMI ju 550k€ 2011-2015 Workpackage leader
Blood imaging: Prediction of survival in Non Small Cell Lung Cancer using blood markers and imaging features: Hypothesis driven approach with prospective validation
KWF 529k€ 2011-2015. PI.
Hypoxic CAIX as a target for imaging and cancer treatment with radiotherapy
KWF 530k€ 2012-2016. PI.
Exploiting intratumour heterogeneity with heterogeneous irradiation KOFL kanker-onderzoek fonds Limburg, 320k€ 2013-2017. Co-PI.
DuCAT, Dutch Network of Computer Assisted Theragnostics
STW 1.289k€ 2014-2019. PI.
Validating predicitive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors (REQUITE)
EU 182k€ 2013-2018. Co-investigator.
Production of a clinical grade "Radiomics" software: Decoding the Tumour Phenotype by non-invasive standard imaging
KWF 258k€ 2013-2015.
Individualized chemo-radiotherapy in locally advanced esophagus cancer: a multifactorial approach
Maastro Atrium 284k€ 2013-2017. PI
Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the optimal Treatment strategy (ELDAPT)
Alpe d’HuZes/KWF 1.298k€ 2014-2020. Co-PI.
An onco-cardiac prospective phase II trial to evaluate of the potential of individualized radiotherapy with echocardiography and smart follow-up technology.
AzM Center of Excellence 112k€ 2014-2017. Co-PI.
Radiation Innovations for Therapy and Education (RADIATE)
EU H2020 510k€ 2014-2018. Co-investigator.
Radiomics of lung cancer (RAIL): non-invasive stratification of tumour heterogeneity for
personalised cancer therapy
EU H2020-SMEINST-2-2014 (PHC-12-2014) 2.442k€ 2015-2019. PI.
A multiparameter radiogenomics-based decision support system for personalized treatment of advanced stage head and neck cancer patients (DESIGN)
Alpe d’HuZes/KWF € 385K 2015-2019. PI
Quantification of hypoxic and metabolic status of NSCLC tumours using [18F] FDG PET/CT imaging: /
are the two imaging modalities complementary? A clinical trial.
Varian Medical Systems €108K 2014-201
Improving the quality of Big Data of radiotherapy by
Open Source Varian Medical Systems €35K 2014-2016. PI
Validation of a open source, web-based patient Decision Aids for patients with prostate cancer
Varian Medical Systems €84K 2014-2016. PI.
Impact of changes in tumor anatomy on dose painting
Varian Medical Systems €72 2014-2015. PI.
Radiomics – Non-invasive STRatification of Tissue heterogeneity of personalized medicine –
STW, k€1.476, 2016-2021. PI.
Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia (HYPOXIMMUNO), ERC advanced
EU, k€2.499, 2016-2021. PI.
Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for
limited metastatic lung cancer (IMMUNOSABR), H2020,
EU, k€5,994, 2017- 2022).
Optimising Radiomics for MRI-based personalised cancer treatment (REACT) SME associate,
EU, k€140, 2017-2018.
A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology “PREDICT” MARIE SKŁODOWSKA-CURIE ACTIONS, Innovative Training Networks (ITN) Call: H2020-MSCA-ITN-2017,
EU M€ 3,86
Imaging-based Big Data for decision support systems for cancer: productization and sustainable research and development of Radiomics products “EURADIOMICS”, Interreg,
EU M€ 3,40